Developer docs
API playgroundTry for free, no card

Search company profiles

SciNeuro

Full company profile

uuid0000uv4

Namestring
SciNeuro
Legal namestring
SciNeuro Pharmaceuticals
Websiteurl
scineuro.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company founded in late 2020 by Min Li (former SVP of Neurosciences R&D at GSK and Johns Hopkins professor) that develops disease-modifying therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). The company's pipeline spans three mechanistic pillars—neurovascular inflammation, proteinopathy, and immune response—delivered through small molecules (SNP318, an Lp-PLA2 inhibitor that completed Phase 1 dosing in late 2023), antisense oligonucleotides (SNP614 targeting LRRK2 for Parkinson's; SNP622 targeting APOE for Alzheimer's), and monoclonal antibodies (SNP201 anti-alpha-synuclein, SNP203 anti-SORT1, SNP210 anti-TDP-43, SNP234 anti-amyloid). A core technical differentiator is the proprietary SNP837 blood-brain barrier (BBB) shuttle platform, described by the company as best-in-class for CNS delivery efficiency and pharmacokinetics, intended to be modularly combined with multiple therapeutic cargo types to improve deep brain biodistribution.

SciNeuro operates a licensing-and-collaboration business model: it discovers and advances programs through preclinical and early clinical stages, then partners with major pharmaceutical companies for late-stage development and commercialization while retaining rights in selected geographies (notably Greater China). Revenue mechanics consist of upfront licensing payments, research funding, development/regulatory/commercial milestone payments, tiered royalties on net sales, and non-dilutive grants. The most consequential deal to date is a January 2026 worldwide licensing and collaboration agreement with Novartis Pharma AG for the amyloid beta-targeted antibody program, valued at up to $1.7 billion ($165 million upfront plus up to $1.5 billion in milestones plus tiered royalties). Earlier license/option agreements include Eli Lilly (alpha-synuclein, Greater China), GSK (Lp-PLA2 inhibitors, worldwide with Greater China retention and GSK option post-PoC), and platform-discovery collaborations with Secarna Pharmaceuticals (LNAplus ASO platform), Alamar Biosciences (Attobody antibody platform), and Mabylon AG (human auto-antibody discovery). Capital formation includes a $100M Series A in December 2020 co-led by LAV and ARCH Venture Partners, a $53M equity round in December 2025 co-led by the same sponsors, and a $5M MJFF grant in November 2025. The company maintains a dual US-China operational footprint with headquarters in Rockville, Maryland and R&D operations in Shanghai's Pudong New District.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease therapeutics, CNS drug development, blood-brain barrier shuttle, antisense oligonucleotide therapy, disease-modifying treatments
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Neurodegenerative Disease Therapeutics (CNS Biopharmaceuticals)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Collaboration Agreements
TypeLicensing Royalties
Description

SciNeuro generates revenue through licensing its proprietary programs to larger pharmaceutical companies. This includes upfront payments, research funding, development and regulatory milestone payments, commercial milestones, and tiered royalties on net sales. Examples include the $165M upfront deal with Novartis plus up to $1.5B in milestones and royalties.

scineuro.com
2Non-Dilutive Research Grants
TypeProfessional Services
Description

The company receives non-dilutive funding through research grants from foundations and organizations, such as the $5M grant from The Michael J. Fox Foundation for Parkinson's Research.

prnewswire.com
3Equity Financing
TypeSubscription Recurring
Description

SciNeuro raises equity capital from venture capital firms and investors to fund R&D operations and pipeline advancement. The company completed a $53M equity financing round in December 2025 and previously raised a $100M Series A in 2020.

biopharmadive.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company developing a portfolio of proprietary investigational therapeutics—small molecules, antibodies, and antisense oligonucleotides—for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and ALS. The pipeline is built around three mechanistic pillars (neurovascular inflammation, proteinopathy, and immune response) and is enabled by a proprietary modular blood-brain barrier (BBB) shuttle platform (SNP837) designed to enhance deep brain delivery of therapeutic cargo across modalities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 1 clinical trial completed for SNP318 with favorable safety profile, strong target engagement, and excellent oral exposure supporting once-daily dosing
+3 more records
Product overview1 text field

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company developing a portfolio of novel investigational medicines for neurodegenerative diseases. The company's pipeline spans discovery to clinical development across three mechanistic pillars: neurovascular inflammation (SNP318 - Lp-PLA2 inhibitor), proteinopathy (SNP201 - alpha-synuclein, SNP234 - beta-amyloid), and immune response (SNP203 - progranulin, SNP614 - LRRK2, SNP622 - APOE, SNP210 - TDP-43). The company's proprietary BBB shuttle technology (SNP837) enables deep brain delivery across multiple therapeutic modalities to enhance the therapeutic potential of pipeline candidates.

Product and service8 records
1SNP201 (Alpha-synuclein antibody)
CategoryTherapeutic Candidate (Monoclonal Antibody)
Description

High-affinity alpha-synuclein antibody that binds preferentially to pathogenic aggregated forms of alpha-synuclein; targets Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Licensed to Eli Lilly for Greater China; SciNeuro holds rights in that region.

2SNP203 (Anti-SORT1 antibody)
CategoryTherapeutic Candidate (Monoclonal Antibody)
Description

Best-in-class anti-SORT1 antibody that restores extracellular progranulin (PGRN) levels by blocking the PGRN-SORT1 interaction, reducing PGRN endocytic clearance; targets frontotemporal dementia (GRN-FTD) and Alzheimer's disease.

3SNP210 (Anti-TDP-43 antibody)
CategoryTherapeutic Candidate (Human Autoantibody)
Description

Human autoantibody with high affinity for disease-variant TDP-43; targets amyotrophic lateral sclerosis (ALS) and certain forms of frontotemporal dementia.

4SNP234 (Anti-amyloid beta antibody)
CategoryTherapeutic Candidate (Monoclonal Antibody)
Description

Next-generation anti-amyloid antibody with exceptional potency and selectivity for toxic aggregated beta-amyloid species over non-pathogenic monomeric forms; targets Alzheimer's disease. Licensed worldwide to Novartis (Jan 2026).

5SNP318 (Lp-PLA2 inhibitor)
CategoryTherapeutic Candidate (Small Molecule)
Description

CNS-penetrant small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential to repair the blood-brain barrier and blood-retinal barrier; targets Alzheimer's disease and macular diseases. Licensed from GSK (June 2022) with worldwide rights retained by SciNeuro.

6SNP614 (LRRK2-targeting antisense oligonucleotide)
CategoryTherapeutic Candidate (Antisense Oligonucleotide)
Description

Chemically modified antisense oligonucleotide (ASO) using locked-nucleic acid (LNA) chemistry that efficiently downregulates LRRK2 mRNA, lowering LRRK2 levels and activities linked to Parkinson's disease development and progression; positioned as a disease-modifying therapy superior to current symptomatic standard of care.

7SNP622 (APOE-targeting antisense oligonucleotide)
CategoryTherapeutic Candidate (Antisense Oligonucleotide)
Description

Potent antisense oligonucleotide (ASO) that reduces APOE expression in relevant human brain cells, targeting Alzheimer's disease by reducing brain APOE4. Developed using Secarna's LNAplus platform under a 2023 research and option agreement.

8SNP837 (BBB Shuttle Platform)
CategoryTechnology Platform (Drug Delivery)
Description

Proprietary modular blood-brain barrier (BBB) shuttle platform that enables therapeutic molecules (e.g., antibodies) to be transported into the CNS, enhancing deep-brain biodistribution, target engagement, and therapeutic potential; designed to be applicable across multiple therapeutic modalities.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Worldwide licensing and collaboration agreement to develop SciNeuro's novel amyloid beta-targeted antibody program for Alzheimer's disease using proprietary BBB shuttle technology. SciNeuro receives $165M upfront plus up to $1.5B in development, regulatory, and commercial milestones, plus tiered royalties. Companies collaborate during early development; Novartis leads subsequent global clinical development and commercialization. Expected to close H1 2026.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2023-03-27
Description

Multi-target research and option agreement for CNS disease therapies using Secarna's LNAplus antisense oligonucleotide discovery platform. Secarna generates and profiles ASO candidates against targets selected by SciNeuro; SciNeuro has option for exclusive worldwide development and commercialization rights.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-06-01
Description

Exclusive worldwide license and option agreement for Lp-PLA2 inhibitors targeting neurodegenerative diseases. SciNeuro receives worldwide license with responsibility for clinical proof-of-concept; GSK has option to reclaim rights excluding Greater China following PoC. Based on clinical findings showing Lp-PLA2 inhibition may improve cognitive function in Alzheimer's disease.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2022-02-15
Description

Multi-program collaboration leveraging Alamar's Attobody platform to discover novel therapeutic antibodies for CNS disease targets. Alamar produces high-affinity antibodies without need for affinity maturation. SciNeuro receives exclusive worldwide rights; Alamar eligible for research payments, milestones, and royalties.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-10-26
Description

Multi-program collaboration and license agreement to discover and develop human auto-antibodies against neurological disease targets including TDP-43 and APOE. SciNeuro gains rights to develop and commercialize in Greater China with option to expand to worldwide. Mabylon brings proprietary human antibody screening and cloning technology.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-04-14
Description

Exclusive license agreement for alpha-synuclein targeted antibody therapies in Greater China. Lilly receives upfront payment plus downstream milestones and royalties; retains all rights outside Greater China. Targets Parkinson's disease and related neurological disorders affecting approximately 3 million patients in Greater China.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for neurodegenerative diseases using a proprietary blood-brain barrier delivery platform (Enzyme Transport Vehicle). Direct competitor in BBB shuttle technology and CNS drug development for Alzheimer's, Parkinson's, and ALS.

TypeDirect peer
Description

Clinical-stage biotechnology company focused on immune system approaches to neurodegenerative diseases, with programs in Alzheimer's, FTD, and Parkinson's. Comparable CNS pipeline structure and similar neuroimmunology focus areas.

TypeDirect peer
Description

Clinical-stage biotech developing protein-targeting therapies for neurodegenerative diseases including Parkinson's (alpha-synuclein), Alzheimer's (amyloid, tau), and ALS. Directly comparable in proteinopathy pipeline strategy and CNS focus.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapeutics for CNS diseases including Alzheimer's, Parkinson's, and ALS. Comparable in CNS-focused pipeline targeting neurodegenerative diseases with innovative delivery approaches.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing treatments for neurodegenerative and neurodevelopmental disorders including Alzheimer's, Parkinson's, and Rett syndrome. Comparable clinical-stage CNS drug developer with small molecule focus.

6Cassava Sciences
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing treatments for Alzheimer's disease, with lead program simufilam and an Alzheimer's diagnostic. Comparable in clinical-stage Alzheimer's-focused CNS pipeline.

TypeEmerging player
Description

Clinical-stage biotechnology company developing regulatory T-cell-based therapies for neurodegenerative diseases including ALS and Alzheimer's. Emerging player with partial overlap in CNS neuroinflammation focus area.

TypeBroad incumbent
Description

Commercial-stage biopharmaceutical company pioneering RNA interference (RNAi) therapeutics. Comparable in antisense oligonucleotide/nucleic acid-based therapeutic modality expertise and CNS pipeline development through partnership with Regeneron.

TypeBroad incumbent
Description

Established leader in antisense oligonucleotide drug discovery and development with multiple approved ASO drugs and broad CNS pipeline. Comparable in ASO therapeutic modality and neurodegenerative disease focus (e.g., tofersen for SOD1 ALS).

TypeEmerging player
Description

Clinical-stage genetic medicines company developing stereopure oligonucleotide therapeutics for CNS diseases including Huntington's, ALS, and Parkinson's. Emerging player in CNS-focused ASO development with comparable therapeutic modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SciNeuro

Neurodegenerative Disease Therapeutics (CNS Biopharmaceuticals)scineuro.com

What SciNeuro does

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company founded in late 2020 by Min Li (former SVP of Neurosciences R&D at GSK and Johns Hopkins professor) that develops disease-modifying therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). The company's pipeline spans three mechanistic pillars—neurovascular inflammation, proteinopathy, and immune response—delivered through small molecules (SNP318, an Lp-PLA2 inhibitor that completed Phase 1 dosing in late 2023), antisense oligonucleotides (SNP614 targeting LRRK2 for Parkinson's; SNP622 targeting APOE for Alzheimer's), and monoclonal antibodies (SNP201 anti-alpha-synuclein, SNP203 anti-SORT1, SNP210 anti-TDP-43, SNP234 anti-amyloid). A core technical differentiator is the proprietary SNP837 blood-brain barrier (BBB) shuttle platform, described by the company as best-in-class for CNS delivery efficiency and pharmacokinetics, intended to be modularly combined with multiple therapeutic cargo types to improve deep brain biodistribution.

SciNeuro operates a licensing-and-collaboration business model: it discovers and advances programs through preclinical and early clinical stages, then partners with major pharmaceutical companies for late-stage development and commercialization while retaining rights in selected geographies (notably Greater China). Revenue mechanics consist of upfront licensing payments, research funding, development/regulatory/commercial milestone payments, tiered royalties on net sales, and non-dilutive grants. The most consequential deal to date is a January 2026 worldwide licensing and collaboration agreement with Novartis Pharma AG for the amyloid beta-targeted antibody program, valued at up to $1.7 billion ($165 million upfront plus up to $1.5 billion in milestones plus tiered royalties). Earlier license/option agreements include Eli Lilly (alpha-synuclein, Greater China), GSK (Lp-PLA2 inhibitors, worldwide with Greater China retention and GSK option post-PoC), and platform-discovery collaborations with Secarna Pharmaceuticals (LNAplus ASO platform), Alamar Biosciences (Attobody antibody platform), and Mabylon AG (human auto-antibody discovery). Capital formation includes a $100M Series A in December 2020 co-led by LAV and ARCH Venture Partners, a $53M equity round in December 2025 co-led by the same sponsors, and a $5M MJFF grant in November 2025. The company maintains a dual US-China operational footprint with headquarters in Rockville, Maryland and R&D operations in Shanghai's Pudong New District.

SciNeuro firmographics

Firmographics
Name
SciNeuro
Legal name
SciNeuro Pharmaceuticals
Website
https://scineuro.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

SciNeuro industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics (CNS Biopharmaceuticals)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Neurodegenerative disease therapeutics
  • CNS drug development
  • Blood-brain barrier shuttle
  • Antisense oligonucleotide therapy
  • Disease-modifying treatments

Where SciNeuro is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices3 records

Markets served

SciNeuro business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Collaboration Agreements: SciNeuro generates revenue through licensing its proprietary programs to larger pharmaceutical companies. This includes upfront payments, research funding, development and regulatory milestone payments, commercial milestones, and tiered royalties on net sales. Examples include the $165M upfront deal with Novartis plus up to $1.5B in milestones and royalties.
  2. Non-Dilutive Research Grants: The company receives non-dilutive funding through research grants from foundations and organizations, such as the $5M grant from The Michael J. Fox Foundation for Parkinson's Research.
  3. Equity Financing: SciNeuro raises equity capital from venture capital firms and investors to fund R&D operations and pipeline advancement. The company completed a $53M equity financing round in December 2025 and previously raised a $100M Series A in 2020.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

SciNeuro product offering

Product offering

Core offering

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company developing a portfolio of proprietary investigational therapeutics—small molecules, antibodies, and antisense oligonucleotides—for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and ALS. The pipeline is built around three mechanistic pillars (neurovascular inflammation, proteinopathy, and immune response) and is enabled by a proprietary modular blood-brain barrier (BBB) shuttle platform (SNP837) designed to enhance deep brain delivery of therapeutic cargo across modalities.

Product overview

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company developing a portfolio of novel investigational medicines for neurodegenerative diseases. The company's pipeline spans discovery to clinical development across three mechanistic pillars: neurovascular inflammation (SNP318 - Lp-PLA2 inhibitor), proteinopathy (SNP201 - alpha-synuclein, SNP234 - beta-amyloid), and immune response (SNP203 - progranulin, SNP614 - LRRK2, SNP622 - APOE, SNP210 - TDP-43). The company's proprietary BBB shuttle technology (SNP837) enables deep brain delivery across multiple therapeutic modalities to enhance the therapeutic potential of pipeline candidates.

Differentiator

Problem solved

Functional benefit

Products and services

  • SNP201 (Alpha-synuclein antibody) High-affinity alpha-synuclein antibody that binds preferentially to pathogenic aggregated forms of alpha-synuclein; targets Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Licensed to Eli Lilly for Greater China; SciNeuro holds rights in that region.
  • SNP203 (Anti-SORT1 antibody) Best-in-class anti-SORT1 antibody that restores extracellular progranulin (PGRN) levels by blocking the PGRN-SORT1 interaction, reducing PGRN endocytic clearance; targets frontotemporal dementia (GRN-FTD) and Alzheimer's disease.
  • SNP210 (Anti-TDP-43 antibody) Human autoantibody with high affinity for disease-variant TDP-43; targets amyotrophic lateral sclerosis (ALS) and certain forms of frontotemporal dementia.
  • SNP234 (Anti-amyloid beta antibody) Next-generation anti-amyloid antibody with exceptional potency and selectivity for toxic aggregated beta-amyloid species over non-pathogenic monomeric forms; targets Alzheimer's disease. Licensed worldwide to Novartis (Jan 2026).
  • SNP318 (Lp-PLA2 inhibitor) CNS-penetrant small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential to repair the blood-brain barrier and blood-retinal barrier; targets Alzheimer's disease and macular diseases. Licensed from GSK (June 2022) with worldwide rights retained by SciNeuro.
  • SNP614 (LRRK2-targeting antisense oligonucleotide) Chemically modified antisense oligonucleotide (ASO) using locked-nucleic acid (LNA) chemistry that efficiently downregulates LRRK2 mRNA, lowering LRRK2 levels and activities linked to Parkinson's disease development and progression; positioned as a disease-modifying therapy superior to current symptomatic standard of care.
  • SNP622 (APOE-targeting antisense oligonucleotide) Potent antisense oligonucleotide (ASO) that reduces APOE expression in relevant human brain cells, targeting Alzheimer's disease by reducing brain APOE4. Developed using Secarna's LNAplus platform under a 2023 research and option agreement.
  • SNP837 (BBB Shuttle Platform) Proprietary modular blood-brain barrier (BBB) shuttle platform that enables therapeutic molecules (e.g., antibodies) to be transported into the CNS, enhancing deep-brain biodistribution, target engagement, and therapeutic potential; designed to be applicable across multiple therapeutic modalities.

Quantifiable outcome

  • Phase 1 clinical trial completed for SNP318 with favorable safety profile, strong target engagement, and excellent oral exposure supporting once-daily dosing
  • +3 more outcomes

Companies that use SciNeuro

Customer profile

Segments2 records

Ideal customer profiles1 record

SciNeuro technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SciNeuro partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship, supporting and core.

  • Novartis Pharma AGflagshipStrategic or Co-development Partner · 12 January 2026Worldwide licensing and collaboration agreement to develop SciNeuro's novel amyloid beta-targeted antibody program for Alzheimer's disease using proprietary BBB shuttle technology. SciNeuro receives $165M upfront plus up to $1.5B in development, regulatory, and commercial milestones, plus tiered royalties. Companies collaborate during early development; Novartis leads subsequent global clinical development and commercialization. Expected to close H1 2026.
  • Secarna PharmaceuticalssupportingTechnology or Integration · 27 March 2023Multi-target research and option agreement for CNS disease therapies using Secarna's LNAplus antisense oligonucleotide discovery platform. Secarna generates and profiles ASO candidates against targets selected by SciNeuro; SciNeuro has option for exclusive worldwide development and commercialization rights.
  • GlaxoSmithKline (GSK)coreOEM/ Whitelabel/ Licensing Partner · 1 June 2022Exclusive worldwide license and option agreement for Lp-PLA2 inhibitors targeting neurodegenerative diseases. SciNeuro receives worldwide license with responsibility for clinical proof-of-concept; GSK has option to reclaim rights excluding Greater China following PoC. Based on clinical findings showing Lp-PLA2 inhibition may improve cognitive function in Alzheimer's disease.
  • Alamar BiosciencessupportingTechnology or Integration · 15 February 2022Multi-program collaboration leveraging Alamar's Attobody platform to discover novel therapeutic antibodies for CNS disease targets. Alamar produces high-affinity antibodies without need for affinity maturation. SciNeuro receives exclusive worldwide rights; Alamar eligible for research payments, milestones, and royalties.
  • Mabylon AGsupportingStrategic or Co-development Partner · 26 October 2021Multi-program collaboration and license agreement to discover and develop human auto-antibodies against neurological disease targets including TDP-43 and APOE. SciNeuro gains rights to develop and commercialize in Greater China with option to expand to worldwide. Mabylon brings proprietary human antibody screening and cloning technology.
  • Eli Lilly & CompanycoreOEM/ Whitelabel/ Licensing Partner · 14 April 2021Exclusive license agreement for alpha-synuclein targeted antibody therapies in Greater China. Lilly receives upfront payment plus downstream milestones and royalties; retains all rights outside Greater China. Targets Parkinson's disease and related neurological disorders affecting approximately 3 million patients in Greater China.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

SciNeuro competitors and assessment

Company assessment

Direct peers

  • Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases using a proprietary blood-brain barrier delivery platform (Enzyme Transport Vehicle). Direct competitor in BBB shuttle technology and CNS drug development for Alzheimer's, Parkinson's, and ALS.
  • Alector: Clinical-stage biotechnology company focused on immune system approaches to neurodegenerative diseases, with programs in Alzheimer's, FTD, and Parkinson's. Comparable CNS pipeline structure and similar neuroimmunology focus areas.
  • Prothena: Clinical-stage biotech developing protein-targeting therapies for neurodegenerative diseases including Parkinson's (alpha-synuclein), Alzheimer's (amyloid, tau), and ALS. Directly comparable in proteinopathy pipeline strategy and CNS focus.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based therapeutics for CNS diseases including Alzheimer's, Parkinson's, and ALS. Comparable in CNS-focused pipeline targeting neurodegenerative diseases with innovative delivery approaches.
  • Anavex Life Sciences: Clinical-stage biopharmaceutical company developing treatments for neurodegenerative and neurodevelopmental disorders including Alzheimer's, Parkinson's, and Rett syndrome. Comparable clinical-stage CNS drug developer with small molecule focus.
  • Cassava Sciences: Clinical-stage biopharmaceutical company developing treatments for Alzheimer's disease, with lead program simufilam and an Alzheimer's diagnostic. Comparable in clinical-stage Alzheimer's-focused CNS pipeline.

Emerging players

  • Coya Therapeutics: Clinical-stage biotechnology company developing regulatory T-cell-based therapies for neurodegenerative diseases including ALS and Alzheimer's. Emerging player with partial overlap in CNS neuroinflammation focus area.
  • Wave Life Sciences: Clinical-stage genetic medicines company developing stereopure oligonucleotide therapeutics for CNS diseases including Huntington's, ALS, and Parkinson's. Emerging player in CNS-focused ASO development with comparable therapeutic modality.

Broad incumbents

  • Alnylam Pharmaceuticals: Commercial-stage biopharmaceutical company pioneering RNA interference (RNAi) therapeutics. Comparable in antisense oligonucleotide/nucleic acid-based therapeutic modality expertise and CNS pipeline development through partnership with Regeneron.
  • Ionis Pharmaceuticals: Established leader in antisense oligonucleotide drug discovery and development with multiple approved ASO drugs and broad CNS pipeline. Comparable in ASO therapeutic modality and neurodegenerative disease focus (e.g., tofersen for SOD1 ALS).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

SciNeuro social profiles

Digital presence

SciNeuro financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SciNeuro leadership team

Management profile

Number of profiles

Profiles12 records

SciNeuro funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SciNeuro M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SciNeuro

What does SciNeuro do?

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company developing a portfolio of proprietary investigational therapeutics—small molecules, antibodies, and antisense oligonucleotides—for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and ALS. The pipeline is built around three mechanistic pillars (neurovascular inflammation, proteinopathy, and immune response) and is enabled by a proprietary modular blood-brain barrier (BBB) shuttle platform (SNP837) designed to enhance deep brain delivery of therapeutic cargo across modalities.

Is SciNeuro a public or private company?

SciNeuro is a private company. It is classified as venture growth investor backed and is currently operating.

When was SciNeuro founded?

SciNeuro was founded in 2020. It employs 11 to 50 people.

Where is SciNeuro based?

SciNeuro is headquartered in Rockville, United States, in the North America region.

How does SciNeuro make money?

Three revenue lines are on record. Licensing and Collaboration Agreements are the primary driver. The others are non-Dilutive Research Grants and equity Financing.

Who are SciNeuro's main competitors?

Direct peers on record are Denali Therapeutics, Alector, Prothena, Voyager Therapeutics, Anavex Life Sciences and Cassava Sciences. Emerging players are Coya Therapeutics and Wave Life Sciences. Broad incumbents are Alnylam Pharmaceuticals and Ionis Pharmaceuticals.

Does SciNeuro have an API?

No public API is recorded for SciNeuro.

What industry is SciNeuro in?

SciNeuro's product category is Neurodegenerative Disease Therapeutics (CNS Biopharmaceuticals). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyNovartis commits $3.2B to subcutaneous deliveryNovartis committed up to $3.223 billion to Alteogen's ALT-B4 technology for converting intravenous biologics into subcutaneous drugs. The payment includes milestones and royalties, with potential reuse across multiple products. Alteogen has signed four licensing agreements in 2026, including with Biogen and GSK.PharmExecJP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the IndustryThe 44th annual JP Morgan Healthcare Conference took place January 12-15 in San Francisco, where major pharmaceutical and biotech companies discussed pipeline strategies and partnerships to address the looming patent cliff, with several announcing new blockbuster drugs expected by 2030. Notable deal activity included Boston Scientific's $14.5 billion acquisition of Penumbra, AbbVie's $5.6 billion licensing agreement with RemeGen for a bispecific antibody, and Novartis's $1.65 billion in combined licensing deals with SciNeuro Pharmaceuticals and Zonsen PepLib Biotech for Alzheimer's and oncology treatments. Executives also highlighted concerns about NIH funding uncertainty and competitive pressure from China, while discussing AI applications and direct-to-consumer sales strategies.The Healthcare Technology Report.SciNeuro and Novartis Sign Global Deal to Advance Alzheimer’s Antibody ProgramSciNeuro Pharmaceuticals has entered into a worldwide licensing and collaboration agreement with Novartis Pharma AG to advance a novel amyloid beta-targeted antibody program for Alzheimer's disease, incorporating SciNeuro's blood-brain barrier shuttle technology. Under the deal, SciNeuro will receive an upfront payment of $165 million plus additional research funding, with potential milestone payments up to $1.5 billion and tiered royalties, while Novartis will assume global development and commercialization responsibilities after early-stage collaboration. The transaction is expected to close in the first half of 2026, subject to customary regulatory conditions.PharmaLiveJPM 2026 witnesses dealmaking optimism despite absence of mega M&AThe 44th Annual J.P. Morgan Healthcare Conference in 2026 highlighted renewed optimism for biopharmaceutical dealmaking despite the absence of major M&A announcements, with Q4 2025 recording a 59.3% uptick in M&A deal value to $80.2 billion and a 35% surge in biotech venture financing to $5 billion. AbbVie led licensing activity with a $5.6 billion deal for RemeGen's Phase II bispecific antibody RC148, while Novartis signed agreements worth over $1.6 billion and $50 million with Chinese biotech firms SciNeuro Pharmaceuticals and Zonsen PepLib Biotech respectively; Aktis Oncology completed the first biopharma IPO of 2026 raising approximately $365 million. Industry experts noted that nearly 50% of US biopharma licensing agreements in 2025 involved in-licensing from China, with the sector entering 2026 primed for potential large M&A as companies seek to offset upcoming patent expiries.SynBioBetaThe Year China Surpassed the USA in Biotech Innovation, Deal Value, and Clinical OutputChina emerged as the dominant force in biotech deal-making at JPM2026, with Chinese biotech firms closing approximately $7.3 billion in deals during the conference, significantly exceeding AI infrastructure investments. The country's biotech sector has widened its lead over the U.S. in clinical trial volume, reaching 7,100–7,700 trials by 2025 compared to 6,200–6,300 in the U.S., and captured roughly 50% of global license-out deal value in 2025, up from a much smaller share previously. Notable major licensing agreements included a $5.6 billion AbbVie–RemeGen Biosciences deal and a $1.6 billion-plus Novartis–SciNeuro Pharmaceuticals agreement.Longevity.TechnologySciNeuro and Novartis ink $1.7b deal for new Alzheimer’s treatmentSciNeuro Pharmaceuticals has granted Novartis an exclusive worldwide license to develop its novel amyloid beta-targeted antibody program for Alzheimer's disease, in a deal worth up to $1.7 billion including $165 million upfront and up to $1.5 billion in development, regulatory and commercial milestones plus tiered royalties. The partnership centers on SciNeuro's proprietary "brain shuttle" technology designed to improve drug delivery across the blood-brain barrier, a fundamental challenge that has limited the effectiveness of existing Alzheimer's therapies. The transaction is expected to close in the first half of 2026, with both companies collaborating during early development before Novartis takes over global clinical development and commercialization.MedCity News6 JPM Announcements You Don’t Want to MissThe J.P. Morgan Healthcare Conference in San Francisco brought together healthcare leaders featuring multiple major announcements across the sector. Nvidia and Eli Lilly announced a $1 billion joint AI innovation lab to accelerate drug discovery, while Novartis struck a $1.7 billion licensing deal with SciNeuro Pharmaceuticals for Alzheimer’s antibody treatments and AbbVie committed $650 million upfront to license a bispecific cancer drug from RemeGen. Additional announcements included generative AI startup Hippocratic AI’s acquisition of Grove AI, VieCure’s $43 million funding round for oncology software, and Baxter’s launch of a new smart stretcher for patient handling.Pharmaceutical TechnologyJPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&AsThe biopharmaceutical industry entered 2026 with renewed optimism for dealmaking at the J.P. Morgan Healthcare Conference held January 12-15, 2026 in San Francisco, with Q4 2025 showing a 59.3% uptick in M&A deal value totaling $80.2bn and a 157% increase in IPO deal volume. AbbVie announced a $5.6bn licensing agreement for RemeGen's Phase II bispecific antibody drug, while Novartis signed deals worth over $1.6bn with China-based SciNeuro Pharmaceuticals and $50m with Zonsen PepLib Biotech for oncology treatments. The industry is shifting toward selective deal-making and licensing agreements rather than mega-M&As, with China emerging as a key source for innovative drugs as US companies in-licensed nearly 50% of their innovative drugs from Chinese developers in 2025.PharmajournalistNovartis Licenses SciNeuro’s Brain-Targeting Alzheimer’s Antibody ProgramSciNeuro Pharmaceuticals has entered into a worldwide licensing agreement with Novartis Pharma AG, granting Novartis exclusive global rights to develop and commercialize SciNeuro's amyloid beta-targeted antibody candidates for Alzheimer's disease, which utilize a proprietary blood-brain barrier shuttle technology to improve drug delivery to the brain. Novartis will pay SciNeuro $165 million upfront and up to an additional $1.5 billion in potential development, regulatory, and commercial milestone payments, plus tiered royalties on future sales, with Novartis assuming full responsibility for global development and commercialization following an initial collaborative phase. The transaction is expected to close in the first half of 2026, subject to customary regulatory approvals including Hart-Scott-Rodino antitrust clearance.BioSpaceDeals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays BusyAbbVie acquired ex-China rights to RemeGen's PD-1/VEGF bispecific for nearly $5 billion and Novartis struck a $1.5 billion deal with China-based SciNeuro Pharmaceuticals as the 2026 J.P. Morgan Healthcare Conference opened. Merck CEO Rob Davis signaled openness to deals in the "multi tens of billions" range while the IPO window reopened with Aktis Oncology debuting and Veradermics and Eikon Therapeutics announcing their own public offering plans. The FDA removed suicide warnings from GLP-1 medication labels after finding no increased risk of suicidal ideation, providing regulatory relief for Eli Lilly and Novo Nordisk.